ReviewSeminars in thrombosis and hemostasis2020
Hematology Laboratory Abnormalities in Patients with Coronavirus Disease 2019 (COVID-19).
Review in Seminars in thrombosis and hemostasis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 66 citations in OpenAlex.
- Genetic patterns related to von Willebrand factor: implications on the need for mechanical ventilation, severity, and death in COVID-19.Frontiers in medicine · 2025Article
- Observational
- In Situ Endothelial SARS-CoV-2 Presence and PROS1 Plasma Levels Alteration in SARS-CoV-2-Associated Coagulopathies.Life (Basel, Switzerland) · 2024Article
- COVID-19: Not a thrombotic disease but a thromboinflammatory disease.Upsala journal of medical sciences · 2024Review
- Confounding role of comorbidities and COVID-19 vaccination uptake in clinical utility of hematological biomarkers in Cameroonian patients infected with SARS-CoV-2.IJID regions · 2023Article
- Article
- Thromboembolic Presentations among Patients Hospitalized to the Intensive Care Unit for Coronavirus Disease 2019 (COVID-19) - A Northern Taiwan Single Center Experience.Acta Cardiologica Sinica · 2023Article
- The Management of COVID-19-Related Coagulopathy: A Focus on the Challenges of Metabolic and Vascular Diseases.International journal of molecular sciences · 2023Review
- To Clot or Not to Clot: Is That the Question?Journal of clinical medicine · 2023Article
- Missense Variants of von Willebrand Factor in the Background of COVID-19 Associated Coagulopathy.Genes · 2023Article
- Article
- Pathology utilisation during COVID-19 outbreaks beyond viral testing: routine coagulation and D-dimer testing.Pathology · 2023Article
- Article
- SARS-CoV-2 Altered Hemorheological and Hematological Parameters during One-Month Observation Period in Critically Ill COVID-19 Patients.International journal of molecular sciences · 2022Article
- Autoimmune Diseases Affecting Hemostasis: A Narrative Review.International journal of molecular sciences · 2022Review
- Coagulation Profile of COVID-19 Patients.Life (Basel, Switzerland) · 2022Review
- Recent Chronology of COVID-19 Pandemic.Frontiers in public health · 2022Review
- COVID-19-related laboratory coagulation findings.International journal of laboratory hematology · 2021Review
- Prevalence of Elevated D-dimer Levels in Confirmed COVID-19 Cases in Intensive Care Unit of a Tertiary Care Centre of Western Nepal.JNMA; journal of the Nepal Medical Association · 2021Article
- Post-coronavirus disease syndrome and disseminated microthrombosis: the role of the von Willebrand factor and antiphospholipid antibodies.Clinics (Sao Paulo, Brazil) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past few months, Coronavirus Disease 2019 (COVID-19) has spread across much of the world leading to a pandemic. Many infected individuals do not experience signs or symptoms, or experience only mild symptoms, whilst a subset experience severe disease, which is often fatal. A number of laboratory tests have been found to be abnormal in hospitalized patients, and some studies suggest some of these tests can predict an unfavorable outcome. These include markers of acute phase reaction (elevated C-reactive protein, erythrocyte sedimentation rate, white blood cell count, fibrinogen, procalcitonin, factor VIII, von Willebrand factor), signs of tissue injury (elevated lactic dehydrogenase, alanine aminotransferase, cardiac troponins), changes in hemostasis and coagulation (elevated D-dimer, prolonged prothrombin time, decreased platelets, decreased antithrombin, elevated factor VIII and von Willebrand factor), and decreased lymphocytes. Additional studies are needed to confirm the most ideal panel of tests, and to confirm the efficiency of laboratory tests to predict clinical outcome, as well as the ideal anticoagulation management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.